Mission Bio's Tapestri Enables Single-Cell Profiling of Residual Disease, Identifying AML Patients Likely to Benefit from Motixafortide in the Multicenter BLAST Trial

Mission Bio's Tapestri Enables Single-Cell Profiling of Residual Disease, Identifying AML Patients Likely to Benefit from Motixafortide in the Multicenter BLAST Trial

Raccontata damorningstar.com